PET/MR Imaging in Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03739281|
Recruitment Status : Recruiting
First Posted : November 12, 2018
Last Update Posted : December 13, 2018
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer||Diagnostic Test: PET/MR Diagnostic Test: PET/CT||Not Applicable|
Lung cancer is the most frequent cancer type and the leading cause of cancer-related death worldwide. Positron emission tomography (PET) coupled with computed tomography (CT) is the standard of care for visualization and staging of lung cancer. Recent clinical introduction of hybrid PET and magnetic resonance (MR) imaging systems has shown potential to improve tumor imaging beyond the limits of PET/CT. However, knowledge about the clinical impact of this new hybrid modality is still limited.
This project aims to investigate how PET/MR may improve the diagnosis and treatment of lung cancer disease, compared to PET/CT: PET/MR may allow early detection of brain and liver metastases, which strongly affects treatment outcome and survival; predictive models based on machine learning may combine image derived biomarkers from PET/MR, histology and health record data, to automatically visualize and characterize the tumor, facilitating computer aided diagnosis and personalized radiotherapy treatment.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Advancing Diagnosis and Treatment for Lung Cancer Patients Using Hybrid PET/MR Imaging and Novel Visualization Tools|
|Actual Study Start Date :||December 12, 2018|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2025|
Nuclear medicine imaging
Patients undergo nuclear medicine imaging with PET/MR and PET/CT.
Diagnostic Test: PET/MR
The included patients are imaged with PET/MR as part of the research protocol.
Diagnostic Test: PET/CT
The included patients are imaged with PET/CT as part of normal clinical routine.
- Sensitivity and specificity of PET/MR vs. clinical routine PET/CT [ Time Frame: 1-2 weeks after the initial inclusion. ]Sensitivity and specificity of PET/MR scans will be compared with in clinical routine PET/CT examinations for lung cancer disease feature prediction.
- Prediction of treatment response and progression-free survival [ Time Frame: 1 year after inclusion. ]We will investigate which PET/MR or PET/CT features are best suited as an imaging biomarker for treatment response evaluation and for progression-free survival 1 year after inclusion.
- Prediction of treatment response and progression-free survival [ Time Frame: 2 years after inclusion. ]We will investigate which PET/MR or PET/CT features are best suited as an imaging biomarker for treatment response evaluation and for progression-free survival 2 years after inclusion.
- Prediction of treatment response and progression-free survival [ Time Frame: 5 years after inclusion. ]We will investigate which PET/MR or PET/CT features are best suited as an imaging biomarker for treatment response evaluation and for progression-free survival 5 years after inclusion.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03739281
|Contact: Rune Sundset, MD, PhD||+47 - firstname.lastname@example.org|
|Contact: Samuel Kuttner, Msc||+47 - email@example.com|
|University Hospital of North Norway||Recruiting|
|Tromsø, Norway, 9037|
|Contact: Rune Sundset +47 - 97 14 14 56 firstname.lastname@example.org|
|Contact: Samuel Kuttner +47 - 77 66 99 53 email@example.com|
|Principal Investigator:||Rune Sundset, MD, PhD||University Hospital of North Norway|